SCHEMBL30765482

SCHEMBL30765482

COc1ccc(CNc2cnc(-c3ccccc3)n(CC(=O)O)c2=O)c(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.50
MAPT P10636 3/20 0.47
TAS1R3 Q7RTX0 1/20 0.46
TAS1R1 Q7RTX1 1/20 0.46
CYP1A2 P05177 6/20 0.45
CYP3A4 P08684 6/20 0.45
CYP2D6 P10635 6/20 0.45
CYP2C19 P33261 5/20 0.45
CLK4 Q9HAZ1 4/20 0.45
CYP2C9 P11712 3/20 0.45
EGLN1 Q9GZT9 3/20 0.45
TSHR P16473 5/20 0.44
ALDH1A1 P00352 4/20 0.44
LMNA P02545 2/20 0.44
HIF1A Q16665 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ASPH Q12797 1/20 0.44
KDM8 Q8N371 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MEN1 O00255 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558534 0.93 KDM4C (0.48) KDM4CMAPTTAS1R3TAS1R1CYP1A2
SCHEMBL30765526 0.89 KDM4C (0.46) KDM4CMAPTTAS1R3TAS1R1CYP1A2
SCHEMBL30765668 0.88 GAA (0.50) KDM4CMAPTTAS1R3TAS1R1CYP1A2
SCHEMBL30765992 0.84 MAPT (0.52) KDM4CMAPTTAS1R3TAS1R1CYP1A2
SCHEMBL30765849 0.81 KDM4C (0.46) KDM4CMAPTTAS1R3TAS1R1CYP1A2
SCHEMBL30765706 0.80 ELANE (0.47) EGLN1ALDH1A1LMNAKDM4EMEN1
SCHEMBL30765910 0.79 PDE4B (0.48) KDM4CMAPTEGLN1TSHRALDH1A1
SCHEMBL30765610 0.77 MAPT (0.52) KDM4CMAPTTAS1R3TAS1R1CYP1A2
SCHEMBL6801188 0.76 SMN1; SMN2 (0.48) MAPTTSHRALDH1A1LMNAKDM4E
SCHEMBL6799310 0.75 RAB9A (0.54) ALDH1A1LMNAKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed